Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Giveback Bill Expected This Session; Will HR 3580 Be Included?

This article was originally published in The Gray Sheet

Executive Summary

The prospects for a Medicare provider giveback package emerging from the Senate this session remain strong despite the failure to attach reimbursement increases to drug benefit legislation, according to legislative staffers

You may also be interested in...



Inpatient Payment Rule Provides No New Tech Add-On Payments For Devices

Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion

Inpatient Payment Rule Provides No New Tech Add-On Payments For Devices

Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion

User Fee Supporters Eye Rx Drug Bill, Other Vehicles In Coming Weeks

Proponents of HR 3580, user fees and language pertaining to reuse of single-use devices are looking beyond the ongoing Medicare prescription drug debate to find a more suitable legislative vehicle before the Senate recesses Aug. 5

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel